Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BI 187004 on Repaglinide and Bupropion PK
NCT02305901Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 187004 in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of repaglinide, Maximum measured concentration of repaglinide and 4 more. Started Dec 2014; status: completed.
02
Drugs
BI 187004
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02305901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305901.